TrialSignal
Clinical trial intelligence report
A Phase 1B Investigator Initiated Study To Evaluate The Preliminary Activity, Safety And Tolerability Of ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers.
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06513624
Status
RECRUITING
Phase
PHASE1
Sponsor
National University Hospital, Singapore
Executive brief
Investment-Ready Snapshot
This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06513624
Indication
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
Modality
small molecule
Target
ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid
Intervention
ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.